{
    "clinical_study": {
        "@rank": "55424", 
        "arm_group": {
            "arm_group_label": "Prolieve", 
            "arm_group_type": "Experimental", 
            "description": "Prolieve\u00ae is a transurethral  microwave   therapy  device  equipped  with automated  controls designed\tto   deliver    microwave    energy    to   the   prostate    and   balloon-administered compression  for the treatment  of symptomatic  BPH.   This device  utilizes  a transurethral catheter  with microwave   antenna  to heat the prostate,  with simultaneous  46 Fr. prostatic urethral   catheter   balloon-administered     compression."
        }, 
        "brief_summary": {
            "textblock": "The primary  objective  of the post-marketing   study is to collect  safety  and\n      effectiveness data  for  5  years  on  subjects  treated  with  Prolieve\u00ae.    The\n      collection   of  5-year  safety information  will be used to evaluate  the occurrence  of\n      any long-term  side effects from the treatment.      The  collection   of  long-term\n      effectiveness    data  on  subjects   treated   with Prolieve\u00ae will provide  information  on\n      the long-term  effects  of treatment  and  time to re- treatment  (any treatment  initiated\n      for BPH  since Prolieve'\"  treatment,  including  a second treatment  with Prolieve\")."
        }, 
        "brief_title": "Post-Marketing Study Using PROLIEVE\u00ae for the Treatment of Benign Prostatic Hyperplasia (BPH)", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Benign Prostate Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with symptomatic BPH.\n\n          -  Peak Urine flow rate <12 ml/sec on voided volume of >125mL.\n\n          -  AUA symptom score value \u22659(9).\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subjects whose pain response has been significantly decreased by any means (because\n             the subject's ability to detect pain is a treatment safety mechanism).\n\n          -  Subject with a history of any illness or surgery that might confound the results of\n             the study \" or impede the successful completion of trial\"\n\n          -  Subject with a history of any illness for which the Prolieve\u00ae treatment may pose\n             additional risk to the subject.\n\n          -  Subject with the confirmed or suspected malignancy of the prostate\n\n          -  Subject with the confirmed or suspected bladder cancer\n\n          -  PSA >10 ng/mL\n\n          -  Subject with previous treatment to the prostate (e.g., surgery, balloon dilation,\n             stents, laser, TUNA, or Indigo prostatectomy) and/or non-metallic urogenital implants\n             (e.g., penile prostheses, artificial urinary sphincters)\n\n          -  Subject with prostate weighing <20 or >80g.\n\n          -  Subject with previous pelvic irradiation or radial pelvic surgery\n\n          -  Subject having large, obstructive middle lobe\n\n          -  Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease.\n\n          -  Subject with urethral stricture and/or bladder stones\n\n          -  Active urinary tract infection.\n\n          -  Subject with neurogenic bladder and/or sphincter abnormalities due to Parkinson's,\n             multiple sclerosis, cerebrovascular accident (CVA), diabetes, or other disease\n             process.\n\n          -  Residual bladder volume >250 mL measured by ultrasound.\n\n          -  Compromised renal function (i.e., serum creatinine levels above 1.8 mg/dL).\n\n          -  Cardiac pacemaker or metallic implants or staples, etc. in the pelvic or femoral\n             area.\n\n          -  Concomitant medicating of the following:\n\n               1. Bladder antispasmodics (Ditropan or Detrol) within one week of treatment, unless\n                  there is documented evidence that the subject has been on the same drug dose for\n                  at least three months with a stable voiding pattern. The drug dose will  not be\n                  altered or discontinued for the entrance into or throughout the study.\n\n               2. 5-alpha reductase inhibitors and gonadotropin releasing hormonal analog.\n\n               3. Alpha blockers, antidepressants, androgens, within one week of treatment.\n\n          -  Subject interested in future fertility/fathering children.\n\n          -  Subject with full urinary retention.\n\n          -  Subject with bleeding disorder or liver dysfunction associated with a bleeding\n             disorder.\n\n          -  Subject with prostatic urethra length of <1.2 cm or >5.5 cm."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02021032", 
            "org_study_id": "101-04-401-01"
        }, 
        "intervention": {
            "arm_group_label": "Prolieve", 
            "description": "Prolieve\u00ae is a transurethral  microwave   therapy  device  equipped  with automated  controls designed\tto   deliver    microwave    energy    to   the   prostate    and   balloon-administered compression  for the treatment  of symptomatic  BPH.   This device  utilizes  a transurethral catheter  with microwave   antenna  to heat the prostate,  with simultaneous  46 Fr. prostatic urethral   catheter   balloon-administered     compression.", 
            "intervention_name": "Prolieve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "BPH", 
        "lastchanged_date": "December 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "felipevalerio@wpuafl.com", 
                    "last_name": "Felipe Valerio", 
                    "phone": "407-992-3170"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Winter Park Urology"
                }, 
                "investigator": {
                    "last_name": "David Jablonski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lesbiavazquez@wpuafl.com", 
                    "last_name": "Lesbia Candelaria", 
                    "phone": "407-422-2728"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Winter Park Urology"
                }, 
                "investigator": {
                    "last_name": "Gary Kalser, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ewilson@nfurology.com", 
                    "last_name": "Elizabeth Wilson", 
                    "phone": "770-752-8632"
                }, 
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "North Fulton Urology"
                }, 
                "investigator": {
                    "last_name": "Lewis Kriteman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trobinson@regionalurology.com", 
                    "last_name": "Tracey Robinson", 
                    "phone": "318-683-0411", 
                    "phone_ext": "173"
                }, 
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }, 
                    "name": "Regional Urology"
                }, 
                "investigator": {
                    "last_name": "Ralph Henderson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nleahymu@yahoo.com", 
                    "last_name": "Nancy Leahy, MD", 
                    "phone": "978-256-9507"
                }, 
                "facility": {
                    "address": {
                        "city": "Chelmsford", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Merrimack Urology Associates PC"
                }, 
                "investigator": {
                    "last_name": "Robert Edelstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ccpurologyresearch@communitycare.com", 
                    "last_name": "Brenda Romeo", 
                    "phone": "518-262-8579"
                }, 
                "facility": {
                    "address": {
                        "city": "Alabany", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Albany Medical College Division of Urology"
                }, 
                "investigator": {
                    "last_name": "Ronald Kaufman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carinialmanzar@yahoo.com", 
                    "last_name": "Carini Perello", 
                    "phone": "212-686-1140"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Midtown Urologic Trials, PC"
                }, 
                "investigator": {
                    "last_name": "Robert Salant, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mtambourides@tmhs.org", 
                    "last_name": "Minna Tambourides", 
                    "phone": "832-522-8312"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Mobley Research Center"
                }, 
                "investigator": {
                    "last_name": "David Mobley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Post-Marketing Study Using PROLIEVE\u00ae for the Treatment of Benign Prostatic Hyperplasia (BPH)", 
        "overall_contact": {
            "email": "varada.bidargaddi@kentron.co", 
            "last_name": "Varada Bidargaddi"
        }, 
        "overall_official": {
            "affiliation": "Jefferson Urology", 
            "last_name": "Perry Weiner, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to re-treatment will be estimated using Kaplan Meier estimation techniques.  The re-treatment rate at years 1 through 5 will be estimated and 95% confidence intervals obtained, and the median time to re-treatment will be estimated.  Subjects who receive re-treatment will be classed as treatment failures.  Subjects who are lost to follow-up will be considered as re-treated at their last known study visit.  In addition, a missing at random (MAR) analysis will be performed.", 
            "measure": "Time to Re-Treatment", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02021032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measured based on the number of subjects who worsened, had no change (1-29%), had a 30% or greater improvement or who are missing, based on the change in AUA total score compared to individual baseline for each follow-up evaluation.  A responder analysis will also be done on peak flow rate (PFR) with the following categories: the number of subjects who worsened, had no change (1-19%), had a 20% or greater improvement or who are missing, based on the change in PFR compared to individual baseline for each follow-up evaluation.", 
            "measure": "Change from Baseline in American Urological Association (AUA) Total Score at 5 years", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Medifocus, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medifocus, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2006", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}